Efficacy and safety of Losigamone (cas 112856-44-7) in partial seizures: a randomized double-blind study

Add time:07/25/2019    Source:sciencedirect.com

The objective of the study was to investigate the efficacy and safety of two different dosages of Losigamone (cas 112856-44-7) (LSG) in add-on treatment of partial seizures. In a multi-center, double-blind, randomized clinical trial, patients received one of three 12-week treatments: placebo, LSG 1200 mg/day, or 1500 mg/day, in addition to up to three standard anticonvulsants after a prospective period of 12 weeks to assess baseline seizure frequency. The primary efficacy measure was the relative reduction of seizure frequency per 4 weeks in the double-blind phase as compared to baseline.In the intention-to-treat population of 264 patients, the relative median reduction of partial seizure frequency was 3.3% for placebo, 19.7% for LSG 1200 mg/day, and 25.3% for LSG 1500 mg/day. The differences of both LSG groups versus placebo were significant (P<0.01, two-tailed). In the responder analysis, 11.8% of the patients in the placebo group, 17.2% in the LSG 1200 mg/day group, and 29.3% in the LSG 1500 mg/day group showed a seizure reduction versus baseline of at least 50%. A positive association between dosage and response was observed (P=0.003). Adverse events during treatment were reported by 58.8% of the patients for placebo, by 62.1% for LSG 1200 mg/day and by 76.1% for LSG 1500 mg/day. Most events in the LSG groups occurred during the first 4 weeks of double-blind (during or immediately after up-titration) and subsided quickly. Over the last 4 weeks of treatment, the incidence of adverse events in the LSG groups was close to the placebo level.Based on the study’s results, LSG is an effective and safe add-on drug for refractory partial epilepsy in adults.

We also recommend Trading Suppliers and Manufacturers of Losigamone (cas 112856-44-7). Pls Click Website Link as below: cas 112856-44-7 suppliers

Prev:The antiepileptic drug Losigamone (cas 112856-44-7) decreases the persistent Na+ current in rat hippocampal neurons
Next:Losigamone (cas 112856-44-7) decreases spontaneous synaptic activity in cultured hippocampal neurons)